Eprobemide

Eprobemide
Clinical data
Trade names	Befol (RU)
Other names	Befol
Routes of; administration	Oral
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name 4-Chloro-N-[3-(4-morpholinyl)propyl]benzamide;
CAS Number	87940-60-1;
PubChem CID	65659;
ChemSpider	59094;
UNII	URX5F7RDER;
ChEMBL	ChEMBL2104298;
CompTox Dashboard (EPA)	DTXSID3046409 ;
Chemical and physical data
Formula	C14H19ClN2O2
Molar mass	282.77 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1COCCN1CCCNC(=O)C2=CC=C(C=C2)Cl;
	InChI InChI=1S/C14H19ClN2O2/c15-13-4-2-12(3-5-13)14(18)16-6-1-7-17-8-10-19-11-9-17/h2-5H,1,6-11H2,(H,16,18); Key:YYFGRAGNYHYWEZ-UHFFFAOYSA-N;

Eprobemide (INN) is a pharmaceutical drug that was used as an antidepressant in Russia (under the brand name Бефол/Befol).^[1] It is a non-competitive reversible inhibitor of monoamine oxidase A^[2]^[3] that exhibits selective action on serotonin deamination.^[4] Eprobemide differs from moclobemide only in the linker that connects the morpholine fragment with the chlorobenzamide — moclobemide has two carbon atoms while eprobemide has three. Its registration was cancelled on December 30, 2003.^[5]